OpGen (OPGN) Hits New 1-Year Low at $0.53
Shares of OpGen Inc (NASDAQ:OPGN) hit a new 52-week low on Tuesday . The company traded as low as $0.53 and last traded at $0.56, with a volume of 69380 shares. The stock had previously closed at $0.88.
A number of analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of OpGen from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a report on Thursday, March 21st. Alliance Global Partners assumed coverage on shares of OpGen in a research note on Friday, March 1st. They issued a “buy” rating and a $2.30 price objective for the company. Finally, HC Wainwright set a $6.00 price objective on shares of OpGen and gave the stock a “buy” rating in a research note on Wednesday, December 5th.
The company has a current ratio of 1.32, a quick ratio of 1.20 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $4.96 million, a P/E ratio of -0.25 and a beta of 1.14.
An institutional investor recently bought a new position in OpGen stock. Bank of New York Mellon Corp acquired a new position in OpGen Inc (NASDAQ:OPGN) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 20,688 shares of the medical research company’s stock, valued at approximately $27,000. Bank of New York Mellon Corp owned 0.24% of OpGen as of its most recent filing with the SEC. 5.47% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “OpGen (OPGN) Hits New 1-Year Low at $0.53” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/opgen-opgn-hits-new-1-year-low-at-0-53/2923998.html.
OpGen Company Profile (NASDAQ:OPGN)
OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.